Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Indibulin

Indibulin given orally once a day for 5 days followed by a 9 day rest

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

38120

The West Clinic, Memphis

98684

Northwest Cancer Specialists, Vancouver

99218

Evergreen Hematology Oncology, Spokane

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Alaunos Therapeutics

INDUSTRY